Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb:13:16-21.
doi: 10.1016/j.cotox.2018.12.002. Epub 2018 Dec 17.

Biogenic Aldehyde-Mediated Mechanisms of Toxicity in Neurodegenerative Disease

Brianna S Cagle  1 , Rachel A Crawford  1 , Jonathan A Doorn  1
Affiliations

Biogenic Aldehyde-Mediated Mechanisms of Toxicity in Neurodegenerative Disease

Brianna S Cagle et al. Curr Opin Toxicol. 2019 Feb.

Abstract

Oxidative decomposition of several biomolecules produces reactive aldehydes. Monoamine neurotransmitters are enzymatically converted to aldehydes via monoamine oxidase followed by further metabolism such as carbonyl oxidation/reduction. Elevated levels of aldehyde intermediates are implicated as factors in several pathological conditions, including Parkinson's disease. The biogenic aldehydes produced from dopamine, norepinephrine and serotonin are known to be toxic, generate reactive oxygen species and/or cause aggregation of proteins such as α-synuclein. Polyunsaturated lipids undergo oxidative decomposition to produce biogenic aldehydes, including 4-hydroxy-2-nonenal and malondialdehyde. These lipid aldehydes, some including an α,β-unsaturated carbonyl, target important proteins such as α-synuclein, proteasome degradation and G-protein-coupled signaling. Overproduction of biogenic aldehydes is a hypothesized factor in neurodegeneration; preventing their formation or scavenging may provide means for neuroprotection.

Keywords: DOPAL; DOPEGAL; Parkinson’s disease; ROS; aldehydes; lipid peroxidation.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest: The authors declare no conflict of interest.

References

    1. Fitzmaurice AG, Rhodes SL, Lulla A, Murphy NP, Lam HA, O’Donnell KC, Barnhill L, Casida JE, Cockburn M, Sagasti A, Stahl MC, Maidment NT, Ritz B, and Bronstein JM, “Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease,” Proc Natl Acad Sci U S A, vol. 110, no. 2, pp. 636–41, January 8, 2013. - PMC - PubMed
    1. Fitzmaurice AG, Rhodes SL, Cockburn M, Ritz B, and Bronstein JM, “Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease,” Neurology, vol. 82, no. 5, pp. 419–26, February 4, 2014. - PMC - PubMed
    1. Ritz BR, Paul KC, and Bronstein JM, “Of Pesticides and Men: a California Story of Genes and Environment in Parkinson’s Disease,” Curr Environ Health Rep, vol. 3, no. 1, pp. 40–52, March, 2016. - PMC - PubMed
    1. Casida JE, Ford B, Jinsmaa Y, Sullivan P, Cooney A, and Goldstein DS, “Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson’s disease,” Chem Res Toxicol, vol. 27, no. 8, pp. 1359–61, August 18, 2014. - PMC - PubMed
    1. Burke WJ, Li SW, Chung HD, Ruggiero DA, Kristal BS, Johnson EM, Lampe P, Kumar VB, Franko M, Williams EA, and Zahm DS, “Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases,” Neurotoxicology, vol. 25, no. 1–2, pp. 101–115, 2004/01//, 2004. - PubMed

LinkOut - more resources